Bristol-Myers Squibb (BMY) was downgraded today to a hold by thestreet.com's quantitative service. We have been positive on the charts and indicators for BMY - see our review of January 12 - where we recommended, "It has been months in the making but it looks like BMY is finally breaking out over the resistance in the $64-$66 area. Traders should stay long and consider increasing their exposure on strength above $67. Risk below $60 and $100 is our price objective for the first half of 2021."
More from Investing
Many stocks with nosebleed valuations shot higher in response to Fed policy becoming more hawkish, while many quality cheaper names sold off.
The Fed backs off on claims that inflation is transitory and sets the stage for future rate hikes.